Articles: Best practise for dealmakers by dealmakers
Best practise for dealmakers by dealmakers. Current Partnering seeks out the best articles from various sources, to keep you updated on partnering best practice.
Genzyme has rejected an $18.5 billion cash offer from Sanofi-Aventis for the biotechnology giant. This equates to a price of $69 per share and follows months of investor rumour and speculation regarding this deal transaction.
Roche has entered into a $1.1 billion collaboration with Aileron to develop Stapled Peptides. Stapled Peptides are a result of Aileron’s peptide stabilization Technology and offer a potential solution to disease targets within virology, inflammation metabolism and CNS.
Quark has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize QPI-1002.
Metabolism deals were one of the dominant headline makers based on headline value in Q2 of 2010. There were a total of 23 deals announced in Q2 related to diabetes. This is reflected in the Q2 Current Partnering 2010 Scorecard which features deals with a headline value of greater than $500 million.
The deal is structured to include an initial payment of $375 million in cash and stock with an additional consideration of $350 million in cash and stock on the achievement of technical and time based milestones through 2012.
Aspen Pharmacare is set to acquire the drug making arm of Australia's Sigma Pharmaceuticals for $804 million. This would provide Aspen with approximately a quarter of Australia's generic drug market.
Seattle Genetics and Genentech have expanded their existing antibody-drug conjugate collaboration, in order to deliver additional preclinical ADC compounds.
Shire’s mission to become the largest specialty pharma company took another step towards reality with the acquisition of gastrointestinal specialty company Movetis, in a deal valued at $565 million.
BIOTECHNICA, Europe's leading annual biotech and life sciences event, will run from 5 to 7 October in Hannover, Germany, with an emphasis on business development and knowledge transfer. Established in 1985, BIOTECHNICA is comprised of a trade fair, a partnering service, a conference, an award competition, and a career program.
Investor power has resulted in Charles River abandoning its proposed acquisition of Wuxi Pharma. Despite promises of considerable cost savings as a result of the deal, investors remained unconvinced the deal was in the comapny’s best interests....
Sanofi-Aventis have announced a microRNA therapeutics alliance with Regulus Therapeutics which is potentially valued at over $750 million dollars.
Oracle Health Sciences has acquired clinical trial computer software and data management solution company Phase Forward in a deal worth $17.00 a share in cash. This a 30 percent premium over the closing share price of $13.08 and represents a deal value of approximately $685 million.
Abbott laboratories strengthend its pharmaceutical pipeline in immunology and onclogy through the acquisition of Facet Biotech for $722 million.
Perrigo has acquired the leading store brand infant formula manufacturer and distributor for $808 million in cash. The geographical network of Perrigo now includes retailers and drug and grocery store channels in the US, Canada, Mexico and China.
Cephalon has once again demonstrated tremendous business acumen and expanded its range of pharmaceutical products and services within the developed and emerging markets with the acquisition of Mepha AG for $615.4 million.
Boehringer Ingelheim will acquire the remaining 40 percent of the equity in the Japanese over-the-counter consumer drug manufacturer SSP in a deal worth $8.12 per share or $913million in total.
Africa’s biggest drug maker Aspen Pharmacare announced in May that it was planning to acquire Sigma Pharmaceuticals in a take over offer worth $589 million.
InVentiv Health, the pharmaceutical and biotechnology outsourcing solution provider has been acquired for a total of $1.1billion in cash by the private equity firm Thomas H Lee Partners.
Abbott laboratories has acquired Indian based Piramal Healthcare Solutions in a cash deal worth a total $3.72 billion. The deal consists of $2.12 billion upfront and annual payments of $400 million for the next four years beginning in 2011.
The makers of Neurofen painkillers and Durex condoms have announced a deal in which Reckitts will acquire SSL in a deal worth $3.9 billion.
Biovail Corp are set to acquire Valeant Pharmaceuticals in a reverse merger. The deal is expected to be worth $3.3 billion and will take advantage of tax breaks to create a company that retains the Valeant name.
This transaction represents a common stock price of $57.50 and is completed after Astellas first tendered an offer of $52.00 per share directly to the OSI Stockholders in March 2010. This offer was rejected despite initially offering a share price of 40% over the premium.
RatioPharm, the sixth largest generic producer worldwide, has been acquired by Teva Pharmaceuticals for $5 billion. This acquisition will promote Teva to become the number two player in the generics market the leading generic company in Europe with a combined portfolio of 500 molecules and 10,000 presentations in 26 counties.
Mylan has acquired Bioniche Pharma for $550 million in cash. Together with Mylan’s unit dose business UDL Laboratories they will merge to form Mylan Institutional. The merger will give access to the North American injectables market as well as leveraging it to the throughout the rest of the world.
Merck KGgA has acquired the outstanding shares of common stock of Millipore Corporation for $107 per share in cash or a total transaction of $7.2 billion. This deal will create...
Comprehensive list of business development events run by leading event organisers. View list
CurrentPartnering is always seeking new contributors - either freelance or publishers. Contact us now.
Do you have a view on the contents of these articles? If so, please contact us with your comments.